Table of Contents
Overview - Before Choosing a BioStatistics CRO
Many sponsors outsource clinical trial biostatistics to specialized biostatistics CROs that provide statistical design, programming, and analysis support.
However, choosing a biostatistics CRO (Contract Research Organization) is not the same as selecting a full-service CRO.
When you outsource clinical trial biostatistics, you are not buying sites or monitors. You are hiring the experts responsible for turning raw clinical trial data into statistical evidence regulators and investigators can trust.
If the biostatistics partner is weak, you will not have confidence in the study results or the answers to your research questions. Timelines slip. SAPs wobble. Outputs come back with holes that regulators or your own clinicians will question.
Choosing the right biostatistics CRO is one of the most important vendor decisions a clinical trial sponsor makes because statistical design, data standards, and analysis quality directly determine whether trial results are credible and submission-ready.
This set of questions is about one thing: helping sponsors shortlist the biostatistical partner before you waste months in RFP cycles and resourcing chaos.
Key Takeaways
Here are five takeaways that capture what actually matters:
You are hiring people, not a company. Questions 1, 2, and 3 exist for one reason: to find out who will actually touch your data and whether they are good enough. If a vendor cannot name the team before the contract is signed, that is your answer.
Standards compliance is not optional. If a vendor is not already working in SDTM and ADaM routinely, you will pay for that gap later in rework, re-mapping, and tense submission timelines. This is not a capability to develop on your study.
How a vendor handles problems tells you more than how they perform when things go smoothly. Questions on messy data, resource crunches, and audit history are specifically designed to surface this. Vague or defensive answers here are more informative than polished answers elsewhere.
Late statistical involvement is a design risk, not just a scheduling issue. A vendor who wants to join after the protocol and eCRF are finalized will spend the rest of the study working around decisions they should have helped shape. Underpowered studies and unplanned re-analyses are often traceable back to this single gap.
What happens after the last table is delivered matters. Code ownership, documentation standards, and handover packages determine whether your study data stays usable for pooled analyses, regulatory responses, or future work. Vendors who treat this as an afterthought create problems you will not discover until you need something two years later.
Information About This Guide
What This Guide Covers
This guide walks through 16 questions every sponsor should ask before selecting a biostatistics CRO (contract research organization), organized across seven areas:
- Experience and Fit
- Data standards and Technical Capabilities
- Timelines & Coordination
- Quality & Oversight
- Study Design & Statistical Rigor
- Handover and Governance
For each question, you will find why it matters, what a solid answer sounds like, and which responses should give you pause. The guide closes with a practical section on how to run the evaluation itself, from written pre-screening through live meetings and scoring.
What this guide does not cover: contract negotiation, budget benchmarking, or full RFP structure. Those come after shortlisting. This guide is about getting to the right shortlist first.
Who This Guide Is For
This guide is written for anyone responsible for selecting a biostatistics CRO for a clinical trial. That includes:
- Sponsors and biotech teams managing vendor selection
- Clinical operations leads overseeing CRO relationships
- Anyone who has been burned by a weak statistical vendor and wants a more structured approach next time
You do not need a biostatistics background to use it. If you work at a larger organization with an established vendor governance program, use it to pressure-test your current evaluation criteria. If you are at a smaller sponsor with limited CRO experience, read it before you start any RFP process.
When to Use This Guide
Use it before you issue an RFP, not after. This guide is built for shortlisting. It also applies when re-evaluating an existing vendor relationship if you are seeing:
- Slipping timelines
- Outputs returning with errors
- Communication that has become slow or unclear
Why 16 questions and not 50
Sixteen questions is deliberate.
- It is enough to cover the main risk areas; experience, quality, standards, timelines, people, tools, and ways of working.
- It is manageable in real conversations. You can work through these in one or two meetings without turning it into an interrogation.
- It forces prioritization. If a topic does not make this list, it is usually better handled later in the RFP or in the contract.
Use these sixteen questions as your core shortlisting set. You can always add your own specific items.
Why Choosing the Right Biostatistics CRO Matters
A weak statistical partner can introduce risks across the entire clinical trial:
- flawed study design
- underpowered analyses
- delays in Statistical Analysis Plan development
- regulatory questions about statistical methodology
- rework when preparing submission datasets
Strong biostatistics CROs help sponsors avoid these risks by ensuring that statistical thinking shapes the study from the beginning.
What Is a Biostatistics CRO?
A biostatistics CRO is a contract research organization that specializes in statistical design, analysis, and reporting for clinical trials.
Biostatistics CROs typically support:
- statistical study design
- sample size calculation and power analysis
- Statistical Analysis Plan (SAP) development
- CDISC dataset preparation (SDTM and ADaM)
- statistical programming and analysis
- tables, listings, and figures (TFLs)
- regulatory statistical support for FDA, EMA, and Health Canada submissions
Sponsors often work with a specialized statistical CRO when:
- the internal statistics team is small
- advanced statistical expertise is required
- submission-ready datasets must be produced quickly
- multiple trials are running simultaneously
What to Look for in a Biostatistics CRO
Before you send a single question, be clear on the basics.
- Biostatistics Expertise and services: You want a CRO with a real biostatistics group, not a sole statistician attached to a programming shop. They should understand current regulatory expectations (FDA, EMA, Health Canada), ICH Statistical Principles (E9), modern statistical methods, and be experienced in the designs you use most often.
- Data management strength: Biostatistics and data management are glued together in practice. Even if the biostatistics CRO will not host the EDC, they must know CDISC (CDASH, SDTM, ADaM) and have a clean way to handle messy data, reconciliation, and mid-study data extracts.
- Therapeutic area experience: A biostatistics firm that lives in oncology thinks and plans very differently from one mostly conducting dermatology or device research. You do not need an exact match between the statistical team’s experience and your therapeutic area, but you need a team that can effectively translate therapeutic subject matter expertise into statistical best practice. Statistical depth should be non-negotiable. Therapeutic experience matters too, but it should be evaluated in terms of whether the team can translate context into sound endpoint, design, and analysis decisions.
- Flexibility and communication: You need a biostatistics partner who can adapt to your governance model, respond quickly when things change, and talk to your team in plain language. not hide behind jargon or ticket systems.
Once those basics are in place, the real shortlisting power comes from the questions you ask.
16 Questions To Ask Before Choosing a BioStatistics CRO
Experience and Fit
Who they are, what they have actually done, and who will be doing your work. These three questions establish whether the vendor is worth continuing the conversation with at all.
1. How many clinical studies have you supported in the last three years?
Why it matters
You want to know if they are actively working on trials that look like yours today, not ten years ago. Recent work shows they are used to current regulatory expectations, current data flows, and current EDC setups.
What you are listening for
- Concrete numbers, not “quite a few.”
- Specific therapeutic areas and indications.
- Clear examples from the last 36 months, not “over the past decade.”
Red flags
- Experience mainly in observational work.
- Old projects used to pad the story.
- Hesitation when you ask about indications or past sponsors.
2. Can you walk me through an example of a statistical analysis you handled end-to-end, and tell me what made it complex?
Why it matters
This reveals how they think when a study gets messy. A good statistician can explain a complex case clearly. What the question was, what made it hard, which options they considered, and why they chose a path.
It also shows whether they can move from theory to decisions. You will see if they can explain trade-offs in a way your clinicians and executives can understand.
What you are listening for
- Real situations like intercurrent events, missing data, composite endpoints, protocol changes, tricky censoring.
- Clear problem solving such as how they framed the issue, what options they weighed, why they chose one.
- Comfortable explaining technical points without hiding behind jargon.
Red flags
- Vague comments like “it was straightforward.”
- Focus only on tables and listings, not on the thinking behind them.
- Inability to describe what made the work complex.
3. Who will actually do the work on our study, and what is their hands-on experience with trials like ours?
Why it matters
You are not hiring a logo. You are hiring a team. This question helps you see if the people who touch your data have enough experience for the study you are running.
It also surfaces bait and switch risk early. If they cannot name the core team or give basic information about their background, you are likely being sold by one group and serviced by another, with weaker skills than promised.
What you are listening for
- Names, roles, and years of experience for each core person.
- Direct experience with similar designs, endpoints, and sample sizes.
- How senior statisticians will stay involved beyond just signing off.
Red flags
- “We will assign a team after we win the work.”
- Very junior programmers with weak senior oversight.
- You only ever meet sales or business development.
Data Standards and Technical Capabilities
CDISC compliance, QC processes, and tool validation. These questions separate vendors who work in a regulated environment from those who are catching up to one.
4. Do you deliver SDTM and ADaM datasets routinely, and are your outputs ready for regulatory submission if needed?
Why it matters
CDISC standards are now expected in most submissions. If they are not used to working this way, you will pay later in rework, extra mapping, and tense timelines near submission.
A vendor that lives in SDTM and ADaM will design data structures and derivations with traceability in mind. That reduces headaches when you need integrated summaries, new analyses, or answers to detailed regulatory questions .
What you are listening for
- Routine delivery of SDTM and ADaM across recent projects.
- Familiarity with Define.xml, controlled terms, and traceability.
- A straightforward “yes” to submission-ready datasets.
Red flags
- Little or no mention of CDISC.
- Standards work is outsourced because the core team cannot handle it.
- “We can learn SDTM/ADaM if needed.”
5. What does your quality control process look like from raw data to final outputs?
Why it matters
Statistics work looks fine until a mistake is spotted in a table that has already been shared. Then trust drops fast. A clear QC process is your main protection against errors that show up in CSR tables, submission packages, or external presentations.
You want to see checks at each stage. from raw data to derived datasets to outputs. This tells you whether errors will be caught early, or only after senior people or regulators see them.
What you are listening for
A real, stepwise approach, for example.
- Independent programming checks.
- Automated checks and validation routines.
- Manual review of shells, logs, listings, and traceability.
- Documented issues and corrections.
Red flags
- “We always check our work,” with no detail.
- The same programmer checking their own code with no second set of eyes.
- No written SOPs or work instructions that guide QC.
6. Which tools and programming environments do you use, and how do you validate them?
Why it matters
Unclear tool setups and untested macros can introduce quiet errors that are hard to trace. You need to know that the tools they use for your study have been tested, documented, and are used in a consistent way across projects.
This also shows whether they can reproduce work later. If you must repeat an analysis for a new health authority or for an extension study, you want confidence that the same tools and code will give the same results.
What you are listening for
- Clear naming of SAS, R, or similar tools.
- How they confirm that tools and macros work as intended.
- How they handle upgrades and changes.
Red flags
- Old software versions with no plan to update.
- No documented process for tool validation.
- “Our programmers just use what they like.”
Timeline and Coordination
How they manage dependencies, respond under pressure, and handle resource crunches. This is where most day-to-day friction in a vendor relationship comes from.
7. How do you make sure timelines don’t slip when multiple vendors or CROs are involved?
Why it matters
Most delays in statistical work are not caused by the statistics team alone. They come from late data, unclear responsibilities, and poor handoffs between vendors. This question tests whether they know how to manage those dependencies, not just complain about them.
You will see if they think ahead about lab data, imaging, eCOA, and EDC extracts. Vendors who can explain how they handle these moving pieces are more likely to keep your TFL delivery date realistic.
What you are listening for
- How they coordinate with EDC providers, central labs, imaging vendors, and others.
- A clear plan for dependencies. what they need, from whom, and by when.
- How they escalate when partners are in danger of being late. The stats team should not wait for another provider to be late. Rather, they should escalate earlier when it “looks like” they will be late.
Red flags
- “We follow the lead CRO.”
- No clear owner for cross-vendor coordination.
- They talk mostly about blame, not about managing risk.
- There is no Project manager dedicated to statistics (timelines, deliverables, budget, vendor coordination, etc)
8. What is your typical response time when study teams send data questions or change requests?
Why it matters
When timelines are tight, slow replies from your statistics vendor can stall decisions and push out key milestones. You need a realistic picture of how fast they respond, and whether that speed is consistent.
Clear response expectations also shape how your teams will work together. If you know what to expect, you can plan meetings, reviews, and data extracts around those rhythms instead of living in crisis mode.
What you are listening for
- Concrete expectations. For example, same-day acknowledgment, 24–48 hours for most questions.
- Examples of how they handled urgent situations.
- How they support crunch periods like database lock or interim analysis.
Red flags
- “We answer as soon as we can.”
- No service-level expectations at all.
- Defensive tone when you ask about communication.
9. How do you handle resource crunches or overlapping studies? What happens if your team becomes overloaded?
Why it matters
Every vendor faces periods where multiple studies peak at the same time. If there is no plan, your trial will compete for attention with others, and quality or timelines will suffer.
By asking this directly, you learn how they protect existing clients when new work comes in, how they cover holidays and staff departures, and whether senior staff will step in when a project is at risk.
What you are listening for
- Project Management, back-up resources and cross-training.
- A clear resourcing model (for example, primary and secondary programmer per study).
- Senior people ready to step in when needed.
Red flags
- “We never have resourcing issues.”
- Heavy use of ad-hoc freelancers with no clear plan.
- No approach for staff turnover, vacations, or sudden absence.
Quality and Oversight
Audits and messy data handling. These two questions reveal how the vendor behaves when things go wrong, which is more telling than how they perform when everything runs smoothly.
10. When were you last audited, and what were the results?
Why it matters
Audits test real practice, not slide decks. This question shows whether their processes stand up when someone independent looks closely at SOPs, documentation, and outputs.
It also tells you how they respond to issues. A vendor who can explain what was found and what they improved afterward is likely to handle future problems in a calm, structured way.
What you are listening for
- Calm and open attitude toward the question.
- Clear recall of who audited them, when, and why.
- Willingness to share summaries and resulting improvements.
Red flags
- “We have never been audited.”
- Evasive answers about findings or follow-up actions.
- “Everything was fine,” with no detail.
11. If something goes wrong or the data comes in messy, how do you typically handle that?
Why it matters
Clinical data is rarely clean. Labs change units, sites key the wrong values, and mid-study changes create gaps. You need to know whether the vendor has a method for dealing with this, or just reacts on the fly.
Their answer shows how they think about triage, communication with data management, and preventing repeated issues. That can make the difference between a short delay and a chain of rework that pushes out deliverables.
What you are listening for
- Concrete stories of messy data and how they cleaned it up.
- Signs of root-cause thinking, not just fire-fighting.
- A structured escalation and resolution process.
Red flags
- “Our data is rarely messy.”
- Blaming other vendors or sponsors in every example.
- No repeatable process for triage and correction.
Study Design and Statistical Rigor
Protocol involvement, SAP process, and regulatory support. This cluster separates vendors who think statistically from those who execute tasks.
12. How early do you prefer to be involved in protocol and SAP development?
Why it matters
Late involvement from statistics often means missed chances to fix design problems before they are baked into the protocol. That can lead to underpowered studies, unclear endpoints, or extra unplanned analyses late in the game.
A vendor who wants early input can help you shape estimands, visit schedules, key endpoints, and sensitivity analyses in a way that matches how the data will be handled later.
What you are listening for
- A clear preference to be involved before protocol finalization or at least before the EDC is released into production.
- Examples where early involvement avoided later rework or re-analysis.
- A view on estimands, sensitivity analyses, and data collection that shows they think ahead.
Red flags
- “We usually join after protocol and eCRF are done.”
- No interest in design choices or data collection decisions.
- They see themselves purely as programmers.
13. What does your Statistical Analysis Plan process look like from first draft to final sign-off?
Why it matters
A weak SAP process leads to vague plans, arguments near database lock, and last minute changes that nobody has fully reviewed. You need to see how they move from concept to a clear, stable document that your clinicians and statisticians both stand behind.
A solid SAP process also makes mid-study changes easier to manage. If everyone knows how changes are proposed, reviewed, and approved, you spend less time in email threads and more time making clean decisions.
What you are listening for
- How they structure SAPs. sections, templates, level of detail.
- Version control, review cycles, and who signs off.
- How they handle changes after SAP approval.
Red flags
- No standard SAP template or approach.
- Informal change tracking (“we keep notes in email”).
- Weak involvement from senior statisticians at SAP stage.
14. How do you support interactions with regulators or data review committees when statistical questions arise?
Why it matters
When health authorities question your design or analysis, you want your statistician to help answer in a calm and clear way. This is hard to fake if they have no experience in these settings.
Their answer will show whether they have helped prepare written responses, briefing books, or slides, and whether they are comfortable speaking in those meetings. That support can reduce the risk of extra requests, re-analysis, or delay to decisions.
What you are listening for
- Experience joining sponsor meetings with agencies or scientific advice bodies.
- Ability to prepare briefing books, responses, and clarifying slides.
- Comfort answering questions live.
Red flags
- “We leave all regulator contact to the sponsor.”
- No examples of handling regulatory questions.
- Nervousness about speaking directly to agencies.
Handover and Governance
Code documentation and meeting structure. These questions matter most for long-term relationships and studies that will need post-delivery support.
15. What is your approach to code, documentation, and handover at the end of the study?
Why it matters
Your study does not end when the last table is delivered. You may need to pool data, run new analyses, respond to external questions, or hand the work to another partner later. Without clear code and documentation, all of that becomes slow and costly.
A good handover approach saves you from being locked into one vendor and lets new statisticians understand what was done without starting from scratch.
What you are listening for
- Clear rules for code structure, comments, and storage.
- Standard templates for specs, derivation documents, and traceability.
- A normal practice of handing over full programming packages, not just outputs.
Red flags
- “We keep the code for internal use.”
- Sparse or unreadable code and specs.
- No clear handover package defined.
16. How do you set up governance, escalation paths, and meeting cadence with sponsor teams?
Why it matters
Even strong technical work can fail if decisions are slow, issues stay buried, or nobody knows who owns what. Governance is how you avoid that.
This question shows whether they have a simple, proven way to run meetings, track actions, and raise issues before they become serious problems. It also helps you see how your internal team will plug into their process day to day.
What you are listening for
- A clear structure. for example, weekly working meetings, monthly oversight calls, and named points of contact.
- Defined escalation paths for issues that block timelines.
- Practical tools. for example, shared trackers, action logs, and decision records.
Red flags
- “We just set up meetings as needed.”
- No named owner for issue logs and decisions.
- Overreliance on email with no shared view of status.
Final Thoughts
Choosing a statistical CRO is one of the few vendor decisions in a clinical trial where the consequences of a poor choice are not obvious until you are deep into the work. By then, fixing it is expensive and slow.
These 16 questions do not replace a thorough RFP or a careful contract review. What they do is help you avoid spending time and money evaluating vendors who should have been removed from the list early on.
A vendor who answers these questions with specifics, examples, and a calm willingness to describe what went wrong in the past is worth your continued attention. A vendor who deflects, speaks only in generalizations, or avoids the harder questions is giving you information too. Act on it.
The goal of shortlisting is not to find a perfect vendor. It is to enter the RFP stage with only the vendors who have demonstrated they can do the work, communicate clearly, and hold up under scrutiny. That is a reasonable standard.
How to use these questions in practice
Here is a clear way to apply this list when you are shortlisting vendors.
1. Pre-screen on paper
- Send the sixteen questions (or a trimmed set) in writing.
- Remove any vendor that gives thin, vague, or copy-paste answers.
2. Deepen in live meetings
- Use the same questions in your live call.
- Ask for examples and stories, not just reassurances.
3. Score what you hear
- For each question, rate vendors on a 1–5 scale.
- Pay special attention to questions about experience, quality, design, and handover.
4. Compare across vendors
- Look for patterns. One vendor may be strong on standards but weak on timelines. Another may be great on communication but light on SAP structure.
- Decide which risks you can live with, and which you cannot.
5. Use red flags as stop signs
- If you see several red flags in the same area, do not talk yourself into ignoring them. Shortlisting is the time to say “no.”
Used well, these sixteen questions will not just help you pick a vendor. They will also sharpen your own expectations as a sponsor about what “good” statistical support should look like on every study you run.
FAQ: Choosing a Biostatistics CRO
What does a biostatistics CRO do?
A biostatistics CRO provides statistical expertise for clinical trials, including study design, statistical analysis plans, statistical programming, and preparation of submission-ready datasets.
When should a sponsor involve a biostatistics CRO?
Ideally during protocol development. Early statistical involvement improves endpoint selection, sample size calculations, and analysis planning.
What is the difference between a full-service CRO and a biostatistics CRO?
A full-service CRO manages clinical trial operations such as site monitoring and project management. A biostatistics CRO focuses specifically on statistical design, analysis, and reporting.
